文献速递前列腺癌

17基因预后检测在当代泌尿外科实践中的应用:观察性队列中期分析结果

Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort.
PubMed 文献 · Urology · 2017-04-25

这项前瞻性多机构研究纳入临床低危前列腺癌患者,评估17基因组织逆转录PCR检测(GPS)对共同决策的影响。前297例有效检测患者中,23%出现初始推荐与共同决策间的转变;GPS检测队列主动监测使用率为62%,未检测基线队列为40%;1年时选择并坚持主动监测的比例分别为55%和34%。医生报告90%病例中GPS有用,检测后患者决策冲突评分下降。

要点

  • GPS检测队列主动监测使用率为62%,未检测基线队列为40%。
  • 1年时选择并坚持主动监测的比例GPS队列为55%,基线队列为34%。
  • 23%患者出现初始推荐与共同决策之间的转变,医生报告90%病例中GPS有用。

核心结论

  • 接受GPS检测的患者较匹配基线组更可能选择并坚持主动监测作为初始管理,GPS有助于指导临床低危前列腺癌的共同决策。

研究设计与样本

  • 前瞻性多机构研究,纳入临床低危前列腺癌患者,使用已验证的17基因组织逆转录聚合酶链反应检测(Genomic Prostate Score,GPS)。
  • 报告前297例有有效17基因检测结果和决策改变数据的患者结局,其中258例有1年结果。
  • 主要终点为初始管理的共同决策和诊断后1年坚持主动监测(AS);AS使用率和坚持率与未接受基因组检测的基线队列比较;次要终点包括检测感知效用和检测前后患者决策冲突。

主要发现

  • 初始推荐与共同决策之间发生转变的患者占23%。
  • GPS检测队列主动监测使用率为62%,未检测基线队列为40%。
  • 1年时选择并坚持主动监测的比例GPS队列为55%,基线队列为34%。
  • 医生报告GPS在90%的病例中有用。
  • 检测后患者平均决策冲突评分下降。

临床怎么用

  • 作者认为,GPS检测有助于指导临床低危前列腺癌的共同决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the impact of genomic testing in shared decision making for men with clinically low-risk prostate cancer (PCa). MATERIALS AND METHODS: Patients with clinically low-risk PCa were enrolled in a prospective, multi-institutional study of a validated 17-gene tissue-based reverse transcription polymerase chain reaction assay (Genomic Prostate Score [GPS]). In this paper we report on outcomes in the first 297 patients enrolled in the study with valid 17-gene assay results and decision-change data. The primary end points were shared decision on initial management and persistence on active surveillance (AS) at 1 year post diagnosis. AS utilization and persistence were compared with similar end points in a group of patients who did not have genomic testing (baseline cohort). Secondary end points included perceived utility of the assay and patient decisional conflict before and after testing. RESULTS: One-year results were available on 258 patients. Shift between initial recommendation and shared decision occurred in 23% of patients. Utilization of AS was higher in the GPS-tested cohort than in the untested baseline cohort (62% vs 40%). The proportion of men who selected and persisted on AS at 1 year was 55% and 34% in the GPS and baseline cohorts, respectively. Physicians reported that GPS was useful in 90% of cases. Mean decisional conflict scores declined in patients after GPS testing. CONCLUSION: Patients who received GPS testing were more likely to select and persist on AS for initial management compared with a matched baseline group. These data indicate that GPS help guide shared decisions in clinically low-risk PCa.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Eure G, Germany R, Given R, et al. Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort. Urology. 2017. PMID: 28454985. doi:10.1016/j.urology.2017.02.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。